Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro

Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering

Volumn 43, Issue 1, 2008, Pages 78-85

  Gajski, Goran ^a   Garaj Vrhovac, Vera ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Atorvastatin; Chromosome aberrations; Comet assay; Peripheral blood human lymphocytes; Sister chromatid exchange

Indexed keywords

BIOASSAY; BLOOD; CHOLESTEROL; CHROMOSOMES; DNA; ELECTRIC FIELDS;

CHROMOSOME ABERRATIONS (CA); COMET ASSAY; CYTOGENETIC ENDPOINTS; HUMAN LYMPHOCYTES; PERIPHERAL BLOOD HUMAN LYMPHOCYTES; SISTER-CHROMATID EXCHANGE (SCE);

CELL CULTURE;

ATORVASTATIN; DNA;

ARTICLE; CELL CULTURE; COMET ASSAY; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; ELECTRIC FIELD; GENOME; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; SISTER CHROMATID EXCHANGE; STRUCTURAL CHROMOSOME ABERRATION;

ADULT; CELLS, CULTURED; CHROMOSOME ABERRATIONS; COMET ASSAY; DNA DAMAGE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTES; PYRROLES; SISTER CHROMATID EXCHANGE;

EID: 37549044704     PISSN: 10934529     EISSN: 15324117     Source Type: Journal    
DOI: 10.1080/10934520701750066     Document Type: Article

References (30)

1. Newman, C.B.; Palmer, G.; Silbershatz, H.; Szarek, M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am. J. Cardiol. 2003, 92, 670-676.
2. Grundy, S.M. The issue of statin safety: where do we stand? Circulation. 2005, 111(23), 3106-3109.
3. Naoumova, R.P.; O'Neill, F.H.; Dunn, S.; Neurwirth, C.K.; Taylor, G.W.; Axelson, M.; Thompson, G.R. Effect of inhibiting HMG-Coa reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur. J. Clin. Invest. 1999, 29, 404-412.
4. Guerin, M.; Lassel, T.S.; Le-Goff, W.; Farnier, M.; Chapman, M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of Cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 189-197.
5. Noseda, G.; Darioli, R.; Keller, U.; Mordasini, R.; Shokry, A.; Schaffhauser, B.; Riesen, W. Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study). Schweiz. Med. Wochenschr. 2000, 130, 889-895.
6. Schrott, H.G.; Knapp, H.; Davila, M.; Shurzinske, L.; Black D. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. Am. Heart. J. 2000, 140, 249-252.
7. Tolman, K.G. The liver and lovastatin. Am. J. Cardiol. 2002, 89, 1374-1380.
8. Omar, M.A.; Wilson, J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmachoter. 2002, 36, 288-295.
9. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B.Jr.; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C.Jr.; Stone, N.J. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110, 227-239.
10. LaRosa, J.C.; Grundy, S.M.; Waters, D.D.; Shear, C.; Barter, P.; Fruchart, J.C.; Gotto, A.M.; Greten, H.; Kastelein, J.J.; Shepherd, J.;Wenger, N.K. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005, 352, 1425-1435.
11. Harangi, M.; Seres, I.; Varga, Z.; Emri, G.; Szilvássy, Z.; Paragh, G.; Remenyik, É. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol. 2004, 60, 685-691.
12. Ajith, T.A.; Soja, M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly actingmutagens. Cell. Biol. Toxicol. 2006, 22, 269-274.
13. Albertini, R.J.; Anderson, D.; Douglas, G.R.; Hagmar, L.; Hemminki, K.; Merlo, F.; Natarajan, A.T.; Norppa, H.; Shuker, D.E.G.; Tice, R.; Waters, M.D.; Aitio, A. ICPS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat. Res. 2000, 463, 111-172.
14. IAEA. Biological dosimetry - chromosomal aberration analysis for dose assessment. Technical Report Series No. 260. International Atomic Energy Agency, Vienna, Austria 1-69, 1986.
15. Latt, S.A.; Allen, J.; Bloom, S.E.; Carrano, A.; Falke, E.; Kram, D.; Schneider, E.; Schreck, R.; Tice, R.; Whitefield, B.; Wolff, S. Sister-chromatid exchanges: a report of the gene-tox program. Mutat. Res. 1981, 87, 17-62.
16. Singh, N.P.; McCoy, M.T.; Tice, R.R.; Schneider, L.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell. Res. 1988, 175, 184-191.
17. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106, 3143-3421.
18. Pyorala, K.; Pedersen, T.R.; Kjekshus, J.; Faergeman, O.; Olsson, A.G.; Thorgeirsson, G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes. Care. 1997, 20, 614-620.
19. Goldber, R.B.; Mellies, M.J.; Sacks, F.M.; Moye, L.A.; Howard, B.V.; Howard, W.J.; Davis, B.R.; Cole, T.G.; Pfeffer, M.A.; Braunwald, E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose in tolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the Care Investigators. Circulation. 1998, 98, 2513-2519.
20. Crick, D.C.; Andres, D.A.; Danesi, R.; Macchia, M.; Waechter, C.J. Geranyl-geraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 1998, 70, 2397-2404.
21. Betti, C.; Davini, T.; Gianessi, L.; Loprieno, N.; Barale, R. Microgel electrophoresis assay (comet test) and SCE analysis in human lymphocytes from 100 normal subjects. Mutat.Res. 1994, 307, 323-333.
22. Fairbairn, D.W.; Olive, P.L.; O'Neill, K.L.; The comet assay: a comprehensive review. Mutat. Res. 1995, 339, 37-59.
23. Collins, A.; Dusinska, M.; Franklin, M.; Somorovska, M.; Petrovska, H.; Duthie, S.; Fillion, L.; Panayiotidis, M.; Raslova. K.; Vaughan, N. Comet assay in human biomonitoring studies - reliability, validation, and applications. Environ. Mol. Mutagen. 1997, 30(2), 139-146.
24. Wojewódzka, M.; Kruszewski, M.; Iwanenko, T.; Collins, A.R.; Szumiel, I. Application of the comet assay for monitoring DNA damage in workers exposed to chronic low-dose irradiation. I. Strand breakage. Mutat. Res. 1998, 416, 21-35.
25. Olive, P.L. DNA damage and repair in individual cells: aplications of the comet assay in radiobiology. Int. J. Rad. Biol. 1999, 75(4), 395-405.
26. Kopjar, N.; Garaj-Vrhovac V. Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical personnel handling antineoplastic drugs. Mutagenesis. 2001, 16(1), 71-78.
27. Hartman, A.; Plappert, U.; Poetter, F.; Suter, W. Comparative study with the alkaline comet assay and the chromosome aberration test. Mutat. Res. 2003, 536, 27-38.
28. Ciaravino, V.; Kropko, M.L.; Rothwell, C.E.; Hovey, C.A.; Theiss, J.C. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat. Res. 1999, 343(2-3), 95-107.
29. Raslova, K.; Dobiasova, M.; Nagyova, A.; Fabry, R.; Rauchova, H.; Dusinska, M. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage. Eur. J. Clin. Pharmacol. 1998, 54, 697-699.
30. Wierzbicki, A.S.; Lumb, P.J.; Chik, G.; Crook, M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with hypercholesterolemia. Int. J. Clin. Pract. 1999, 53, 609-611.